Compare CECO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | CELC |
|---|---|---|
| Founded | 1966 | 2011 |
| Country | United States | United States |
| Employees | 1540 | N/A |
| Industry | Pollution Control Equipment | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.2B |
| IPO Year | 2002 | 2017 |
| Metric | CECO | CELC |
|---|---|---|
| Price | $64.74 | $65.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $111.86 | ★ $156.91 |
| AVG Volume (30 Days) | 744.6K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.67 | N/A |
| Revenue Next Year | $35.70 | $1,322.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.85 | $45.15 |
| 52 Week High | $101.24 | $151.02 |
| Indicator | CECO | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 28.70 |
| Support Level | $59.46 | N/A |
| Resistance Level | $65.97 | $96.39 |
| Average True Range (ATR) | 3.47 | 4.58 |
| MACD | -0.76 | -0.94 |
| Stochastic Oscillator | 4.20 | 10.57 |
CECO Environmental Corp is an industrial company, serving industrial air, industrial water, and energy transition markets. It offers various engineered and configured products and solutions, including dampers and diverters, selective catalytic reduction systems, severe-service and industrial cyclones, dust collectors, thermal oxidizers, filtration systems, wet and dry scrubbers, water treatment packages, industrial silencers, etc. These products are offered through brands like Western Airducts, WK, Wakefield Acoustics, Transcend, Verantis, and others. The company's reportable segments are: Engineered Systems, which derive maximum revenue, and Industrial Process Solutions. Geographically, it derives key revenue from the U.S., followed by the Netherlands, the UK, China, and other markets.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.